Modified Compound definition

Modified Compound means (i) a compound that results from the Compound Modification process that is not a Bi-Functional Compound or (ii) any Functional Fragment of such compound.
Modified Compound means any article of potential research, therapeutic, prophylactic, diagnostic or agricultural interest, including nanobody derivatives, or engineered modifications containing a ligand- binding domain or utilizing a complementarity determining region or any other sub-portion of an Original Compound, either in its original form or as modified or optimized for commercial utility. Such optimization could include, but is not limited to, protein fusions to create new activity or functionality for any purpose, alterations or fusions to increase expression, modify stability, PK, or biodistribution; functionalization with active moieties or toxins; individual or multiple amino-acid mutations to increase binding or stability, reduce immunogenicity or toxicity, or otherwise enhance suitability for the commercial utility.
Modified Compound has the meaning set forth in Section 5.2.

Examples of Modified Compound in a sentence

  • The Company shall have the option to acquire all rights to such Modified Compound.

  • If the Company determines to acquire such rights, the Company shall tender to Lilly one hundred percent (100%) of the cost incurred by Lilly for such development, and such Modified Compound (or any product containing such Modified Compound) shall be deemed and treated as a Product for purposes of this Agreement.

  • Except as expressly set forth on Exhibit C or in the Services Agreement, Lilly shall have no responsibility to make or maintain any filings with any Drug Regulatory Agency with respect to Compound, Modified Compound or Product.

  • In the event Lilly is a party to any existing agreements relating to research or development of Compound, Modified Compound or Product that will not be terminated by Lilly as of the Effective Date (other than the agreements, if any, listed on Exhibit B), the responsibilities of the Parties with respect to such agreements shall be as set forth on Exhibit E.

  • If the Company determines to acquire such rights, the Company shall tender to Lilly one hundred percent (100%) of the cost incurred by Lilly for such development and such Modified Compound (or any product containing such Modified Compound) shall be deemed and treated as a Product for purposes of this Agreement.

  • If the Company does not exercise its option to acquire rights to such Modified Compound, Lilly may, but shall not be obligated to, continue the development and Lilly shall own all rights thereto.

  • The provisions of Section 2.5(c) below shall be applicable to such Modified Compound.

  • If the Company does not exercise its option to acquire rights to such Modified Compound, Lilly may, but shall not be obligated, to continue the development, and Lilly shall own all rights thereto.

  • Notwithstanding anything expressed or implied in this Agreement to the contrary (including, without limitation, the foregoing provisions of this paragraph), Lilly shall not retain or otherwise have any right to use any Modified Compound identified, discovered or developed by the Company or any of its Affiliates or sublicensees for any purpose whatsoever, including, without limitation, to identify, discover, develop, make, have made, use or sell any Bi-Functional Compound.

  • Licensed Technology with respect to Compound, Modified Compound and Product in accordance with the provisions of this Agreement (including, without limitation, the licenses set forth in the foregoing clauses (i) through (iv) of this Section 2.1), but only if and to the extent that any such practice or use of the Lilly Licensed Technology would, absent this non-exclusive license, infringe one or more of such patents Controlled by Lilly.


More Definitions of Modified Compound

Modified Compound means any bivalent, monospecific, monoclonal, and monoepitopic antibody derived from the Compound having [*****]. Under this Section, a Modified Compound may be made by employees of Dermira or its Affiliates solely or jointly with a Third Party, including a Sublicensee, or solely by a Sublicensee (a “Dermira Modified Compound”), by employees of Roche or its Affiliates solely or jointly with a Third Party (a “Roche Modified Compound”), or jointly by employees of Dermira and Roche or Affiliates of either with or without a Third Party (a “Joint Modified Compound”).
Modified Compound means a Compound that Pieris modifies pursuant to Section 3.4.
Modified Compound means any analog, derivative, or modified version of a Collaboration Compound that is generated by or on behalf of Lilly or any of its Affiliates (other than by Merus or its Affiliates during the Research Term), in each case that is directed against the applicable Lilly Target Pair, but excluding such Lilly Target Pair together with a third Target (and, for clarity, Lilly is not licensed under the terms of this Agreement to generate any such multi-specific compound), and excluding any analog, derivative, or modified version of a Collaboration Compound where the modification is [*]. For clarity, where a Modified Compound generated by or on behalf of Lilly or any of its Affiliates is [*], such compound shall be considered a Modified Compound for all purposes hereunder.
Modified Compound means with respect to the Research Period or thereafter any chemical substance prepared by ONO, which modulates the production of [CONFIDENTIAL TREATMENT REQUESTED] and [CONFIDENTIAL TREATMENT REQUESTED] by binding selectively to melanocortin receptor 1, using chemical synthesis through use of the TREGA Technology or CONFIDENTIAL TREATMENT REQUESTED (i) [CONFIDENTIAL TREATMENT REQUESTED]; (ii) [CONFIDENTIAL TREATMENT REQUESTED]; (iii) [CONFIDENTIAL TREATMENT REQUESTED]; (iv) [CONFIDENTIAL TREATMENT REQUESTED]; and (v) [CONFIDENTIAL TREATMENT REQUESTED]; "Analog" herein shall mean a substance differing from a TREGA Material by replacement of a [CONFIDENTIAL TREATMENT REQUESTED] by an analogous element (i.e. [CONFIDENTIAL TREATMENT REQUESTED] vice versa, one [CONFIDENTIAL TREATMENT REQUESTED] for another, a [CONFIDENTIAL TREATMENT REQUESTED], and [CONFIDENTIAL TREATMENT REQUESTED], or [CONFIDENTIAL TREATMENT REQUESTED] in an aromatic ring), "Bioisostere" herein shall mean the interchange of [CONFIDENTIAL TREATMENT REQUESTED], [CONFIDENTIAL TREATMENT REQUESTED], [CONFIDENTIAL TREATMENT REQUESTED] and [CONFIDENTIAL TREATMENT REQUESTED] group and other well established bioisosteric interchanges and "Homolog" herein shall mean a compound differing from a TREGA Material by a [CONFIDENTIAL TREATMENT REQUESTED] or [CONFIDENTIAL TREATMENT REQUESTED].

Related to Modified Compound

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Exempt compound means the same as defined in Rule 2.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Certified components means components of X-ray systems which are subject to regulations promulgated under Public Law 90-602, the “Radiation Control for Health and Safety Act of 1968,” the Food and Drug Administration.

  • Compounds means any or all of the following chemicals, as the context requires:

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Replacement Candidate means any Candidate Introduced by the Agency to the Client to fill the Engagement following the Introduction of another Candidate whose Engagement either did not commence or was terminated during the first 12 weeks of the Engagement;

  • Antibody means a molecule comprising or containing one or more immunoglobulin variable domains or any fragments, derivatives, variants or modifications thereof that bind to the same antigen.

  • Drug Substance means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.

  • MSAA Indicator Technical Specifications document means, as the context requires, either or both of the document entitled “Multi-Sector Service Accountability Agreement (MSAA) 2019-20 Indicator Technical Specifications November 5, 2018 Version 1.3” and the document entitled “Multi-Sector Service Accountability Agreement (MSAA) 2019-20 Target and Corridor-Setting Guidelines” as they may be amended or replaced from time to time;

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Biosimilar Product means, with respect to a Licensed Product and on a country-by-country basis, a product that [***].

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • low protein modified food product means a food product that is specially formulated to have less than one gram of protein per serving and is intended to be used under the direction of a Practitioner for the dietary treatment of an inherited metabolic disease, but does not include a natural food that is naturally low in protein; and

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Non-Microsoft Product means any third-party-branded software, data, service, website or product, unless incorporated by Microsoft in a Product.

  • medicinal product means any substance or combination of substances presented for treating or preventing disease in human beings or animals and any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans or in animals;

  • Compound of Concern means a contaminant that, based on generally available information, may be emitted to the atmosphere in a quantity from any source at the Facility that is significant either in comparison to the relevant Ministry Point of Impingement Limit or if a Ministry Point of Impingement Limit is not available for the compound then, based on generally available toxicological information, the compound has the potential to cause an adverse effect as defined by the EPA at a Point of Impingement.